Search Results

You are looking at 61 - 70 of 1,553 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation

Juliana E. Hidalgo-López, Rashmi Kanagal-Shamanna, L. Jeffrey Medeiros, Zeev Estrov, C. Cameron Yin, Srdan Verstovsek, Sergej Konoplev, Jeffrey L. Jorgensen, Mohammad M. Mohammad, Roberto N. Miranda, Chong Zhao, John Lee, Zhuang Zuo, and Carlos E. Bueso-Ramos

myelofibrosis (MF). 3 Bone marrow (BM) specimens from these patients usually show characteristic findings, including atypical megakaryocytic hyperplasia with or without reticulin fibrosis. JAK2 V617F mutation also has been reported in chronic myelomonocytic

Full access

Impact of NCI-Mandated Scientific Review on Protocol Development and Content

Ning Ning, Jingsheng Yan, Xian-Jin Xie, and David E. Gerber

following characteristics: year, disease under study, phase and type (interventional/noninterventional), and sponsor type (institutional/industrial). Institutional trials included investigator-initiated trials with a local study chair or a study chair at

Full access

A Hospital-Wide Intervention to Improve Compliance With TNM Cancer Staging Documentation

Jason H. Lee, Tariq Mohamed, Celia Ramsey, Jihoon Kim, Shelly Kane, Kathryn A. Gold, Farhoud Faraji, and Joseph A. Califano III

association of patient, provider, and treatment team characteristics, including 1- or 2-month deadline, with the prevalence of and time to staging. Patient characteristics included age, sex, race, and Charlson comorbidity index (CCI) score. Provider

Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

therapies, such as chemotherapy, endocrine therapy, trastuzumab, and bisphosphonates, on OS in patients with breast cancer. 4 , 5 Provided with basic inputs of an individual patient’s clinicopathologic characteristics, PREDICT provides personalized

Full access

Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer

Vinayak Muralidhar, Paul J. Catalano, Gally Reznor, Brandon A. Mahal, Toni K. Choueiri, Christopher J. Sweeney, Neil E. Martin, Clair J. Beard, Yu-Wei Chen, Michelle D. Nezolosky, Karen E. Hoffman, Felix Y. Feng, Quoc-Dien Trinh, and Paul L. Nguyen

, treatment, and survival data in addition to patient-specific demographic characteristics, covering 28% of the US population and 97% of incident cancers. 12 SEER was linked to Medicare administrative data, which contains insurance claims data for patients

Full access

Telemedicine Adoption in an NCI-Designated Cancer Center During the COVID-19 Pandemic: A Report on Patient Experience of Care

Krupal B. Patel, Amir Alishahi Tabriz, Kea Turner, Brian D. Gonzalez, Laura B. Oswald, Heather S.L. Jim, Oliver T. Nguyen, Young-Rock Hong, Nasrin Aldawoodi, Biwei Cao, Xuefeng Wang, Dana E. Rollison, Edmondo J. Robinson, Cristina Naso, and Philippe E. Spiess

the study period into the same 4 time intervals. Statistical Analyses Patient characteristics were summarized using descriptive statistics, including median and range for continuous measures and proportions and frequencies for categorical

Full access

Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States

Iman K. Berrahou, Ava Snow, Megan Swanson, and Juno Obedin-Maliver

selected because of their particular relevance to the SGM population with regard to enumeration of protections in nondiscrimination policies across federal and state laws. Analyses were performed to determine whether cancer center characteristics impacted

Full access

Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial

Cindy Neuzillet, Olivier Bouché, Christophe Tournigand, Benoist Chibaudel, Lucile Bauguion, Leïla Bengrine-Lefevre, Daniel Lopez-Trabada Ataz, May Mabro, Jean-Philippe Metges, Denis Péré-Vergé, Thierry Conroy, Astrid Lièvre, Morgan Andre, Françoise Desseigne, François Goldwasser, Julie Henriques, Amélie Anota, and Pascal Hammel

study ( supplemental eAppendix 1 ), leading to the current version of the document. Clinical and biologic characteristics as well as baseline HRQoL scores were described in the overall, modified intention-to-treat [mITT] populations (mITT1: patients with

Full access

Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging?

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

backward selection of variables at a significance level of P <.10. An alpha threshold of 0.05 was chosen for statistical significance. Statistical analyses were performed using SPSS Statistics, version 24.0 (IBM Corp). Results Patient Characteristics A

Full access

Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco

between 2006 and 2012 in the National Cancer Database (NCDB). The NCDB collects information from >1,500 Commission on Cancer centers and captures >70% of incident cancer cases in the United States. 11 We abstracted patient characteristics, including age